R&D channel feed

CRO Fortrea 'dis­putes the ac­cu­ra­cy' of Ace­lyrin's claims about im­munol­o­gy drug tri­al con­duct

Last year
Outsourcing

Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Last year
Financing

Ab­b­Vie is gun­ning for ac­cel­er­at­ed ap­proval of an­ti­body-drug con­ju­gate af­ter pos­i­tive PhII da­ta

Last year
Pharma

Ar­ri­vo bags $45M Se­ries B to fund ma­jor de­pres­sion late-stage test and PhII-ready pan­cre­ati­tis as­set

Last year
Financing

Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

Last year
Startups

Eli Lil­ly’s Dan Skovron­sky on oral GLP-1, ‘slow­er ramp’ for Alzheimer’s and deals on ‘un­der­ap­pre­ci­at­ed’ as­sets

Last year
People

FDA to make de­ci­sion about Karuna's schiz­o­phre­nia drug by next Sep­tem­ber

Last year
FDA+

Im­muno­vant takes on ar­genx, J&J with plans to test FcRn in­hibitor in mul­ti­ple par­al­lel tri­als af­ter PhI win 

Last year

No­var­tis ex­ecs high­light progress of slim­mer pipeline af­ter San­doz spin­off

Last year
Pharma

Mer­ck stokes pneu­mo­coc­cal ri­val­ry with Pfiz­er, re­veal­ing up­dat­ed 21-va­lent vac­cine da­ta

Last year
Pharma

Novo­cure to lay off 200 work­ers, nar­row pipeline for elec­tric fields can­cer ther­a­py

Last year
People

Bris­tol My­ers bets $100M on Avid­i­ty's RNA ther­a­pies for car­dio­vas­cu­lar dis­eases

Last year
Deals
Pharma

Flag­ship opens hub, plants roots in the UK as gov­ern­ment aims to boost life sci­ence ecosys­tem

Last year
Startups

Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

Last year

Ace­lyrin says CRO Fortrea made er­rors in tri­al of lead im­munol­o­gy drug izok­ibep

Last year

De­spite fail­ing its PhII test, Xenon sees fu­ture for ma­jor de­pres­sion drug

Last year

Feng Zhang's lat­est gene edit­ing trawl reels in 188 new CRISPR sys­tems

Last year
Discovery
Cell/Gene Tx

Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Last year

Af­ter pulling Blenrep from US mar­kets, GSK plots a come­back with PhI­II mul­ti­ple myelo­ma tri­al suc­cess

Last year

Sanofi, Re­gen­eron say Dupix­ent suc­ceeds in an­oth­er late-stage COPD study, set­ting up fil­ing for FDA ap­proval

Last year
Pharma

En­trada's Duchenne study re­mains on hold in US as biotech com­pletes dos­ing of two co­horts in UK tri­al

Last year

Flag­ship-found­ed Evelo Bio­sciences will dis­solve af­ter find­ing no 'vi­able al­ter­na­tive'

Last year
People

FDA warns Cipla's al­buterol in­haler plant af­ter thou­sands of com­plaints

Last year
FDA+
Manufacturing

J&J, Gen­mab re­veal first-line da­ta for Darza­lex Faspro, plus new man­tle cell lym­phoma re­sults for Im­bru­vi­ca-Ven­clex­ta: #ASH23

Last year
Pharma
First page Previous page 62636465666768 Next page Last page
A service from the Financial Times